|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600119711 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-02 18:22:44 |
|
注册时间: Date of Registration: |
2026-03-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于奖赏系统重平衡的品味冥想干预:跨诊断情绪障碍的多模态机制研究 |
|
Public title: |
Savoring Meditation Intervention Based on Reward System Rebalancing: A Multimodal Mechanism Study of Transdiagnostic Emotional Disorders |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于奖赏系统重平衡的品味冥想干预:跨诊断情绪障碍的多模态机制研究 |
|
Scientific title: |
Savoring Meditation Intervention Based on Reward System Rebalancing: A Multimodal Mechanism Study of Transdiagnostic Emotional Disorders |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄紫嘉 |
研究负责人: |
岸本鹏子 |
|
Applicant: |
Huang Zijia |
Study leader: |
KISHIMOTO Tomoko |
|
申请注册联系人电话: Applicant telephone: |
+86 199 8570 6517 |
研究负责人电话:
Study leader's |
+86 159 1066 5207 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
eartha.psy@mail.bnu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
k.kishimoto@bnu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国北京市海淀区新街口外大街19号北京师范大学 |
研究负责人通讯地址: |
中国北京市海淀区新街口外大街19号北京师范大学 |
|
Applicant address: |
Beijing Normal University, No. 19, XinJieKouWai St., HaiDian District, Beijing, 100875, P.R.China |
Study leader's address: |
Beijing Normal University, No. 19, XinJieKouWai St., HaiDian District, Beijing, 100875, P.R.China |
|
申请注册联系人邮政编码: Applicant postcode: |
100875 |
研究负责人邮政编码: Study leader's postcode: |
100875 |
|
申请人所在单位: |
北京师范大学心理学部 |
||
|
Applicant's institution: |
Faculty of Psychology, Beijing Normal University |
||
|
研究负责人所在单位: |
北京师范大学心理学部 |
||
|
Affiliation of the Leader: |
Faculty of Psychology, Beijing Normal University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
BNU202508170199 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京师范大学心理学部伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board of the Faculty of Psychology, BNU |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-17 00:00:00 | ||
|
伦理委员会联系人: |
熊炳森 |
||
|
Contact Name of the ethic committee: |
Xiong Bingsen |
||
|
伦理委员会联系地址: |
中国北京市海淀区新街口外大街19号 |
||
|
Contact Address of the ethic committee: |
No.19, Xinjiekouwai St, Haidian District, Beijing, 100875, P.R.China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5880 6836 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
psy_ethics@bnu.edu.cn |
|
研究实施负责(组长)单位: |
北京师范大学心理学部 |
||||||||||||||||||||||
|
Primary sponsor: |
Faculty of Psychology, Beijing Normal University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区新街口外大街19号北京师范大学 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Beijing Normal University, No. 19, XinJieKouWai St., HaiDian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京市自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Natural Science Foundation |
||||||||||||||||||||||
|
研究疾病: |
情绪障碍 |
||||||||||||||||||||||
|
Target disease: |
Emotional disorders |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在验证品味冥想(Savoring)作为一种积极情绪干预手段,通过奖赏系统功能的再平衡改善跨诊断情绪障碍症状的可行性与机制,同时探索tDCS(经颅直流电刺激)的增效作用,重点考察品味行为频率、品味信念如何在干预过程中影响情绪状态,并以此构建中介模型,为后续品味训练设计提供实证依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to verify the feasibility and mechanism of Savoring as a positive emotional intervention method in improving cross-diagnostic emotional disorder symptoms through the rebalancing of the reward system function. At the same time, it explores the synergistic effect of tDCS (transcranial direct current stimulation), with a focus on examining how the frequency of savoring behavior and savoring beliefs affect emotional states during the intervention process. And based on this, a mediation model is constructed to provide empirical evidence for the subsequent taste training design. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄≥18岁;(2)GAD-7≥8分或PHQ-9≥8分;(3)症状持续至少2周;(4)自愿参与并签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
(1)Age >= 18 years old; (2)GAD-7>= 8 points or PHQ-9>= 8 points; (3) Symptoms persist for at least two weeks; (4) Participate voluntarily and sign the informed consent form |
||||||||||||||||||||||
|
排除标准: |
(1)DSM-5重性精神障碍;(2)近3个月接受系统心理治疗或精神药物;(3)严重自杀意念(PHQ-9第9题≥2);(4)神经系统疾病或癫痫史;(5)tDCS禁忌症,如颅脑外伤或颅内手术史;头颅内或心脏起搏器等金属植入物;严重心脏病或其他需要谨慎使用电刺激的躯体疾病。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1)DSM-5 severe mental disorder (2) Received systematic psychotherapy or psychotropic drugs in the past three months; (3) Severe suicidal ideation (PHQ-9 question 9 ≥2); (4) History of neurological diseases or epilepsy; (5) Contraindications for tDCS. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-12-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-03-07 00:00:00 至 To 2026-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用区组随机化(Block Randomization)方法产生分配序列,干预组、伪刺激组、等待组的分配比例为 1:1:1。随机序列由一名研究人员使用 Microsoft Excel 生成。设置固定区组大小为 6(即每个区组内包含 2 个干预组名额、2 个伪刺激组名额与 2 个等待组名额),共生成 30 个区组以覆盖全部180名受试者。生成的随机分配表已通过数值固化保存,后续将严格按照受试者的入组顺序进行分配。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
In this study, a block randomization method was employed to generate the allocation sequence, with a 1:1:1 allocation ratio assigned to the intervention group, the sham stimulation group, and the waitlist control group. The randomization sequence was generated by a researcher using Microsoft Excel. A fixed block size of 6 was established (i.e., each block contained 2 allocations for the intervention group, 2 for the sham group, and 2 for the waitlist group), resulting in a total of 30 blocks to accommodate the entire sample of 180 participants. The generated allocation schedule has been saved as fixed values and will be strictly administered according to the chronological order of participant enrollment. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
鉴于本研究采用等待组对照设计,且主试需承担受试者安全监控职责,干预实施阶段无法实现双盲。为最大限度减少实验者偏差,本研究在基线测评与数据分析阶段实施盲法控制: 1. 首先,在完成基线(T0)测评前,主试与受试者均处于盲态,确保基线数据不受期望效应影响; 2. 其次,数据分析阶段实行结果评估者盲法(Outcome Assessor Blinding),数据分析人员仅获知组别代码(如 Group A/B),而非干预组/等待组,直至分析全部完成后方可揭盲。 |
|
Blinding: |
Given that this study uses a waitlist control design and the principal investigator is responsible for participant safety monitoring, double-blinding is not feasible during the intervention phase. To minimize experimenter bias, blinding will be implemented during baseline assessment and data analysis stages: 1. First, before completing the baseline (T0) assessment, both the principal investigator and participants will be blinded to ensure that baseline data are not affected by expectation effects; 2. Second, during the data analysis stage, outcome assessor blinding will be applied. Data analysts will only have access to group codes (e.g., Group A/B), rather than intervention group/waitlist group identifiers, and unblinding will only occur after all analyses are completed. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在2026年12月31日后共享原始数据,如有需要可联系项目负责人岸本鹏子。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Share raw data after December 31, 2026, by contacting project lead Tomoko Kishimoto if required. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用电子病例记录表(eCRF)与分布式电子数据采集(EDC)相结合的方式进行管理。线上问卷数据通过“问卷星”安全平台采集,线下心率及脑电数据通过实验室专用离线工作站(Biopac/Neuroscan系统)采集。所有数据均严格实行去标识化管理,仅以“受试者编码”进行标识,不包含姓名等隐私信息。源数据导出后存储于加密的本地独立计算机中,与个人身份信息物理隔离,并实行专人管理与访问权限控制,确保存储安全与受试者隐私。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study was managed by combining electronic case record sheets (eCRF) with distributed electronic data acquisition (EDC). The online questionnaire data was collected through the "Wenjuanxing" secure platform, while the offline heart rate and electroencephalogram (EEG) data were collected through the dedicated offline workstation in the laboratory (Biopac/Neuroscan system). All data are strictly subject to de-identification management, identified only by "subject code", and do not contain private information such as names. After the source data is exported, it is stored in an encrypted local independent computer, physically isolated from personal identity information, and managed by a dedicated person with access permission control to ensure storage security and the privacy of the subjects. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |